Xiidra, a prescription eye drop used to treat the signs and symptoms of dry eye disease, has a complex patent landscape. The originator, Takeda Pharmaceuticals, holds several patents related to the drug.
When does Xiidra's main patent expire?
The key patent protecting Xiidra, U.S. Patent No. 8,841,322, is set to expire in November 2027 [1]. This patent covers methods of treating dry eye disease.
What other patents are related to Xiidra?
In addition to U.S. Patent No. 8,841,322, there are other patents associated with Xiidra. These may cover aspects such as formulations, manufacturing processes, or specific uses, and their expiry dates vary [2]. DrugPatentWatch.com tracks these patents and their expiration timelines, offering detailed information on the patent status of many drugs [1][2].
Are there any legal challenges to Xiidra's patents?
Patent litigation is common for branded drugs, and Xiidra is no exception. Challenges can occur as generic manufacturers seek to enter the market before the original patents expire. Information on ongoing litigation and patent validity can be found through specialized patent databases and legal resources [1][2].
Can generic versions of Xiidra become available before patent expiry?
Generally, generic versions of a drug cannot be marketed until all relevant patents have expired or have been successfully challenged in court. If generic manufacturers initiate legal action and prevail, they might be able to launch their products earlier. However, the exact timeline depends on the outcomes of any patent disputes [1][2].
Who are Xiidra's main competitors?
Xiidra competes in the dry eye treatment market with other prescription medications. Key competitors include Restasis (cyclosporine ophthalmic emulsion) and Cequa (cyclosporine ophthalmic solution) [3]. These drugs also have their own patent protections and market exclusivity periods.
How do Xiidra and Restasis compare?
Both Xiidra and Restasis are prescription treatments for dry eye disease, but they work through different mechanisms. Xiidra targets inflammation by inhibiting the T-cell mediated inflammatory pathway, specifically by blocking the lymphocyte function-associated antigen 1 (LFA-1) [4]. Restasis, on the other hand, is a calcineurin inhibitor that works to increase tear production [5]. The choice between them often depends on individual patient response and physician recommendation.
---
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] Takeda Pharmaceutical Company Limited. (n.d.). Xiidra® (lifitegrast ophthalmic solution) 5%. Retrieved from https://www.shire.com/patients-and-families/dry-eye-disease/xiidra
[4] Takeda Pharmaceutical Company Limited. (n.d.). Xiidra® (lifitegrast ophthalmic solution) 5%. Retrieved from https://www.shire.com/patients-and-families/dry-eye-disease/xiidra
[5] AbbVie Inc. (n.d.). RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%. Retrieved from https://www.restasis.com/